Imovax Polio

Imovax Polio

vaccine, poliomyelitis


sanofi pasteur


Zuellig Pharma
Full Prescribing Info
Poliomyelitis vaccine.
One dose (0.5 ml) contains: (See table.)

Click on icon to see table/diagram/image

IMOVAX POLIO may contain traces of neomycin, streptomycin and polymycin B (see Contraindications).
Excipients/Inactive Ingredients: 2-phenoxyethanol, formaldehyde, medium 199 Hanks, hydrochloric acid or sodium hydroxide for pH adjustment.
The 2-phenoxyethanol is contained in a solution of 2-phenoxyethanol at 50% in ethanol.
The medium 199 Hanks (without phenol red) is a complex mixture of amino acids (including phenylalanine), mineral salts, vitamins, and other components (such as glucose), supplemented with polysorbate 80 and diluted in water for injections.
Pharmacotherapeutic Group: Vaccine against poliomyelitis. ATC Code: J07BF03.
Pharmacology: Pharmacodynamics: The vaccine is prepared from poliovirus types 1, 2 and 3 cultured on Vero cells, purified and inactivated by formaldehyde.
One month after primary vaccination (3 doses), seroprotection rates were at 100% for types 1 and 3 polioviruses and at 99% to 100% for type 2.
For infants, the booster dose (4th dose) led to a large increase in titres with seroprotection rates of 97.5% to 100% for the three types of polioviruses.
Four to five years after the booster dose, 94 to 99% of subjects had protective titres.
In primed adults, a booster injection is followed by an anamnestic response.
For the most part, these data comes from studies done with combined vaccines containing poliomyelitis vaccine.
Immunity lasts for at least 5 years after the 4th injection.
Pharmacokinetics: Not applicable.
Toxicology: Preclinical Safety Data: Non-clinical data revealed no special hazard for humans based on conventional acute toxicity, repeat dose toxicity and local tolerance studies.
This vaccine is indicated for the prevention of poliomyelitis in infants, children and adults, for primary and booster vaccination.
IMOVAX POLIO must be used according to effective official recommendations.
Dosage/Direction for Use
Posology: Pediatric population: Primary vaccination: One dose at the age of 2 and 4 months.
Booster: One dose at the age of 11 months.
From 6 weeks of age, IMOVAX POLIO may be administered following the 6-, 10-, 14-week schedule, as per the recommendations of the Expanded Programme on Immunization of the World Health Organisation.
Adult population: Primary vaccination: 2 doses of 0.5 ml at an interval of two months.
Booster: First booster: 8 to 12 months after the second injection.
Please refer to official recommendations for any further boosters.
Method of administration: Administration is performed preferably via the intramuscular (IM) route, or via the subcutaneous (SC) route.
Intramuscular injection will be preferably performed in the antero-lateral side of the thigh in young children and in the deltoid muscle in children, adolescents and adults.
For instructions on use, handling and disposal, see Cautions for Usage.
Not applicable.
Hypersensitivity to the active substances or to any of the excipients of the vaccine or to a vaccine containing the same substances, to neomycin, streptomycin or polymyxin B.
Common transient contraindications to any vaccination: in case of fever or acute illness, it is best to postpone vaccination.
Special Precautions
Do not inject via the intravascular route: make sure the needle does not penetrate a blood vessel.
As with all injectable vaccines, IMOVAX POLIO must be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
As with all injectable vaccines, appropriate medical treatment must be readily available and close supervision provided should a rare anaphylactic reaction occur following administration of the vaccine.
Immunosuppresive treatment or an immunodeficiency condition may induce a reduced immune response to the vaccine. It is then recommended to wait until the end of the treatment before vaccinating or to make sure that the subject is well protected. Nevertheless, vaccination of subjects with chronic immunodeficiency such as HIV infection is recommended even if the immune response may be limited.
IMOVAX POLIO may also be recommended for subjects in whom oral vaccine is contraindicated, and as a booster for subjects previously vaccinated with the oral vaccine.
The potential risk of apnoea and the need for respiratory monitoring for 48-72 h should be considered when administering the primary immunisation series to very premature infants (born ≤ 28 weeks of gestation) and particularly for those with a previous history of respiratory immaturity. As the benefit of vaccination is high in this group of infants, vaccination should not be withheld or delayed.
Effects on Ability to Drive and Use Machines: No studies on the effects on the ability to drive and use machines have been performed.
Use In Pregnancy & Lactation
Pregnancy: Given clinical data, this vaccine may be prescribed during pregnancy in high risk situations.
Breastfeeding: This vaccine can be used during breastfeeding.
Fertility: No fertility studies were performed.
Adverse Reactions
The adverse events are ranked according to the MedDRA terminology (by System Organ Class) and under headings of frequency using the following convention: Very common: ≥ 10%; Common: ≥ 1% and < 10%; Uncommon: ≥ 0.1% and < 1%; Rare: ≥ 0.01% and < 0.1%; Very rare: < 0.01%; Not known: cannot be estimated from the available data.
Based on spontaneous reporting, certain undesirable events were very rarely reported following the use of IMOVAX POLIO. Because events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure. This is why these undesirable events are ranked under the << Not known >> frequency.
The events listed as follows were observed during clinical studies or were spontaneously reported after marketing.
The most common adverse events following administration of this vaccine are local injection-site reactions (pain, redness, induration) and fever over 38.1°C.
Immune system disorders: Not known: type I hypersensitivity reaction to one of the components of the vaccine, such as urticaria, angioedema, anaphylactic reaction or anaphylactic shock.
Psychiatric disorders: Not known: agitation, somnolence and irritability in the first hour or days following vaccination and disappearing rapidly.
Nervous system disorders: Not known: convulsions (isolated or associated with fever) in the days following vaccination, headache, moderate and transient paresthesia (mainly in the lower limbs) in the two weeks following vaccination.
Skin and subcutaneous tissue disorders: Not known: rash.
Musculoskeletal and connective tissue disorders: Not known: mild and transitory arthralgia, and myalgia have been reported in the days following vaccination.
General disorders and administration site conditions: Very common: injection-site pain, fever over 38.1°C. Common: injection-site redness. Uncommon: injection-site induration. Not known: lymphadenopathy, local injection-site reactions such as oedema that can occur in the 48 hours following vaccination and lasting one or two days.
Complementary information concerning particular populations: Apnoea in very premature infants (born ≤ 28 weeks of gestation) (see Precautions).
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.
Drug Interactions
There are no known risks of administering IMOVAX POLIO with other usual vaccines during the same vaccination session. In case of concomitant administration, different syringes and separate injection sites should be used.
Caution For Usage
Instructions for use, handling and disposal: Verify that the vaccine is clear and colourless. Do not use the vaccine if it has a cloudy appearance.
For syringes without attached needles, the needle must be fitted firmly to the syringe, rotating it by a one quarter turn.
Any unused product or waste material should be disposed of in accordance with local requirements.
Incompatibilities: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.
Store in a refrigerator (2°C - 8°C) in order to protect from light. Do not freeze.
Shelf-Life: 3 years.
ATC Classification
J07BF03 - poliomyelitis, trivalent, inactivated, whole virus ; Belongs to the class of poliomyelitis viral vaccines.
Vaccine (inj) 0.5 mL/dose (clear and colourless suspension in prefilled syringe) x 1's.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in